What Receptor Does Pembrolizumab Target?
Pembrolizumab (Keytruda) inhibits the programmed cell death protein 1 (PD-1) receptor. It binds directly to PD-1 on T cells, blocking its interaction with PD-L1 and PD-L2 ligands. This prevents immune suppression, allowing T cells to attack cancer cells.
How Does PD-1 Inhibition Work in Cancer Treatment?
PD-1 is an immune checkpoint receptor that downregulates T-cell activity when engaged by PD-L1 on tumor cells. Pembrolizumab's monoclonal antibody structure competitively inhibits this binding, reactivating antitumor immunity. Approved for over 30 indications, including melanoma and non-small cell lung cancer, based on trials showing improved survival.
Does It Affect Other Receptors?
No, pembrolizumab is specific to PD-1. It does not inhibit PD-L1 (targeted by drugs like atezolizumab) or CTLA-4 (targeted by ipilimumab). Dual checkpoint inhibitors combine PD-1 and CTLA-4 blockade for synergistic effects.
What Happens in Patients with PD-L1 Expression?
Tumor PD-L1 levels predict response; high expression (>50%) correlates with better outcomes in pembrolizumab monotherapy. FDA approvals often require PD-L1 testing via IHC assays like 22C3.
Common Side Effects from PD-1 Inhibition?
Immune-related adverse events occur in 10-20% of patients, including colitis, pneumonitis, and hypothyroidism, due to unchecked T-cell activity. Managed with corticosteroids; severe cases (grade 3-4) affect ~5%.
How Does Pembrolizumab Compare to Nivolumab?
Both are PD-1 inhibitors with similar efficacy (e.g., ~20-40% response rates in NSCLC), but pembrolizumab has a fixed 200-400 mg q3-6w dosing vs. nivolumab's weight-based. Head-to-head trials show no major survival differences.
[1] https://www.keytruda.com/
[2] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-adult-pediatric-patients-mismatch-repair-deficient-solid-tumors
[3] https://pubmed.ncbi.nlm.nih.gov/25977399/ (KEYNOTE-001 trial on PD-1 mechanism)